Switch theme
Sign up to access all valuation multiples
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
2020
63
LTM Revenue $0.8M
LTM EBITDA -$96.5M
$390M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ATAI Life Sciences has a last 12-month revenue (LTM) of $0.8M and a last 12-month EBITDA of -$96.5M.
In the most recent fiscal year, ATAI Life Sciences achieved revenue of $0.3M and an EBITDA of -$145M.
ATAI Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ATAI Life Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | $0.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$96.5M | XXX | -$145M | XXX | XXX | XXX |
| EBITDA Margin | -11572% | XXX | -47016% | XXX | XXX | XXX |
| EBIT | -$103M | XXX | -$102M | XXX | XXX | XXX |
| EBIT Margin | -12355% | XXX | -33171% | XXX | XXX | XXX |
| Net Profit | -$132M | XXX | -$149M | XXX | XXX | XXX |
| Net Margin | -15771% | XXX | -48464% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ATAI Life Sciences's stock price is $2.
ATAI Life Sciences has current market cap of $462M, and EV of $390M.
See ATAI Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $390M | $462M | XXX | XXX | XXX | XXX | $-0.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ATAI Life Sciences has market cap of $462M and EV of $390M.
ATAI Life Sciences's trades at 1267.0x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate ATAI Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ATAI Life Sciences has a P/E ratio of -3.5x.
See valuation multiples for ATAI Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $462M | XXX | $462M | XXX | XXX | XXX |
| EV (current) | $390M | XXX | $390M | XXX | XXX | XXX |
| EV/Revenue | 467.8x | XXX | 1267.0x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -3.8x | XXX | -3.8x | XXX | XXX | XXX |
| EV/Gross Profit | 467.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.5x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | -4.7x | XXX | -4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialATAI Life Sciences's last 12 month revenue growth is 26%
ATAI Life Sciences's revenue per employee in the last FY averaged $5K, while opex per employee averaged $1.6M for the same period.
ATAI Life Sciences's rule of 40 is -11538% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ATAI Life Sciences's rule of X is -11507% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ATAI Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | -11572% | XXX | -47016% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -11538% | XXX | -46990% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -11507% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18005% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33271% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ATAI Life Sciences acquired XXX companies to date.
Last acquisition by ATAI Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . ATAI Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ATAI Life Sciences founded? | ATAI Life Sciences was founded in 2020. |
| Where is ATAI Life Sciences headquartered? | ATAI Life Sciences is headquartered in United States of America. |
| How many employees does ATAI Life Sciences have? | As of today, ATAI Life Sciences has 63 employees. |
| Who is the CEO of ATAI Life Sciences? | ATAI Life Sciences's CEO is Mr. Srinivas G. Rao, M.D.,PhD. |
| Is ATAI Life Sciences publicy listed? | Yes, ATAI Life Sciences is a public company listed on NAS. |
| What is the stock symbol of ATAI Life Sciences? | ATAI Life Sciences trades under ATAI ticker. |
| When did ATAI Life Sciences go public? | ATAI Life Sciences went public in 2021. |
| Who are competitors of ATAI Life Sciences? | Similar companies to ATAI Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ATAI Life Sciences? | ATAI Life Sciences's current market cap is $462M |
| What is the current revenue of ATAI Life Sciences? | ATAI Life Sciences's last 12 months revenue is $0.8M. |
| What is the current revenue growth of ATAI Life Sciences? | ATAI Life Sciences revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of ATAI Life Sciences? | Current revenue multiple of ATAI Life Sciences is 467.8x. |
| Is ATAI Life Sciences profitable? | Yes, ATAI Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ATAI Life Sciences? | ATAI Life Sciences's last 12 months EBITDA is -$96.5M. |
| What is ATAI Life Sciences's EBITDA margin? | ATAI Life Sciences's last 12 months EBITDA margin is -11572%. |
| What is the current EV/EBITDA multiple of ATAI Life Sciences? | Current EBITDA multiple of ATAI Life Sciences is -4.0x. |
| What is the current FCF of ATAI Life Sciences? | ATAI Life Sciences's last 12 months FCF is -$82.2M. |
| What is ATAI Life Sciences's FCF margin? | ATAI Life Sciences's last 12 months FCF margin is -9857%. |
| What is the current EV/FCF multiple of ATAI Life Sciences? | Current FCF multiple of ATAI Life Sciences is -4.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
